Other androgen levels, like DHEA, were also reduced, and depression and anxiety levels improved by 55% and 21%, respectively, according to the study in The Journal of the American Osteopathic Association. “There are effective pharmacologic options for managing PCOS. However, they come with the potential for some significant side effects,” says Diana Speelman, PhD, Associate...
Tag: <span>autosomal dominant polycystic kidney disease (ADPKD)</span>
Post
Kidney disease triggers cognitive impairment, even in early stages
ERA-EDTA The link between brain dysfunction and advanced kidney disease was first noted in 1930, so it is not a new finding. Experts spoke of ‘dialysis dementia’ or ‘uremic encephalopathy’. What is new, however, is the finding that mild cognitive impairment (MCI) may already be present in earlier stages of CKD, affecting approximately one in two CKD patients (prevalence varies in studies between...
Post
New findings on tolvaptan as autosomal dominant polycystic kidney disease treatment
A phase 3 trial studying the effects of tolvaptan has found that the drug slowed the rate of decline in kidney function in patients with the most common form of polycystic kidney disease, a condition with no cure. The results are published today in the New England Journal of Medicine. Autosomal dominant polycystic kidney disease is...
Post
Cancer drug may benefit patients with inherited form of kidney disease
A cancer drug called bosutinib may inhibit the growth of cysts in patients with autosomal dominant polycystic kidney disease (ADPKD), according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings point to a potential new treatment strategy for affected patients, but the long-term benefits remain to...